Tango Therapeutics Inc (TNGX) Stock Price, Quote & News

Latest News on TNGX

Jan 30, 2025, 7:00 AM EST - 14 hours ago

Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference

Jan 23, 2025, 5:44 AM EST - 7 days ago

Tango Therapeutics: Chance For A Short Squeeze

Dec 3, 2024, 7:00 AM EST - 2 months ago

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 27, 2024, 7:00 AM EST - 2 months ago

Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 6, 2024, 7:05 AM EST - 3 months ago

Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Nov 6, 2024, 7:00 AM EST - 3 months ago

Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program

Sep 10, 2024, 12:45 PM EDT - 5 months ago

Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data

Aug 28, 2024, 7:00 AM EDT - 5 months ago

Tango Therapeutics to Participate in Upcoming Investor Conferences

Aug 7, 2024, 7:00 AM EDT - 6 months ago

Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Jun 5, 2024, 7:00 AM EDT - 8 months ago

Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

May 23, 2024, 9:18 AM EDT - 9 months ago

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

May 23, 2024, 7:19 AM EDT - 9 months ago

Tango Therapeutics to stop development of cancer therapy

May 23, 2024, 7:00 AM EDT - 9 months ago

Tango Therapeutics Announces Discontinuation of TNG348 Program

May 8, 2024, 7:00 AM EDT - 9 months ago

Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

Mar 18, 2024, 7:00 AM EDT - 11 months ago

Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights

Mar 5, 2024, 4:47 PM EST - 11 months ago

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024

Jan 31, 2024, 7:00 AM EST - 1 year ago

Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Jan 25, 2024, 12:46 PM EST - 1 year ago

Tango Therapeutics: Making Its Way Into Clinic With 4 Innovative Cancer Drugs

Jan 4, 2024, 2:47 AM EST - 1 year ago

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

Nov 13, 2023, 7:00 AM EST - 1 year ago

Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting

Nov 8, 2023, 7:00 AM EST - 1 year ago

Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights

Nov 7, 2023, 7:00 AM EST - 1 year ago

Tango Therapeutics to Present at the Jefferies London Healthcare Conference

Oct 23, 2023, 6:26 PM EDT - 1 year ago

Circling Bank On Tango Therapeutics

Sep 6, 2023, 7:00 AM EDT - 1 year ago

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers

Aug 29, 2023, 5:08 PM EDT - 1 year ago

Tango Therapeutics Announces Updates to Its Board of Directors

Aug 10, 2023, 7:30 AM EDT - 1 year ago

Tango Stock Surges On Peer Data Merits Excitement And Perspective

Aug 10, 2023, 7:00 AM EDT - 1 year ago

Tango Therapeutics Announces $80 million Private Placement Financing

Aug 7, 2023, 7:00 AM EDT - 1 year ago

Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights

Jul 26, 2023, 7:29 PM EDT - 1 year ago

Tango Therapeutics: Partial Phase 1 Data Has Not Helped

Jul 24, 2023, 7:00 AM EDT - 1 year ago

Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers

Jul 10, 2023, 7:00 AM EDT - 1 year ago

Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors

May 9, 2023, 7:00 AM EDT - 1 year ago

Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

Apr 18, 2023, 4:30 PM EDT - 1 year ago

Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting

Apr 3, 2023, 7:00 AM EDT - 1 year ago

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant Cancers

Mar 27, 2023, 7:00 AM EDT - 2 years ago

Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights

Mar 14, 2023, 8:11 PM EDT - 2 years ago

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting

Mar 10, 2023, 10:15 PM EST - 2 years ago

Tango Therapeutics Announces Limited Exposure to Silicon Valley Bank

Feb 21, 2023, 11:55 AM EST - 2 years ago

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Tango Therapeutics, Inc (TNGX) Investigation

Jan 27, 2023, 3:30 PM EST - 2 years ago

Tango Therapeutics: Upcoming Proof Of Concept Data Is A Major Catalyst

Jan 25, 2023, 7:00 AM EST - 2 years ago

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additional Business Updates

Nov 14, 2022, 4:11 PM EST - 2 years ago

Tango Therapeutics: Behind The Recent Momentum

Nov 10, 2022, 7:00 AM EST - 2 years ago

Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights

Oct 19, 2022, 7:00 AM EDT - 2 years ago

Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 5, 2022, 8:10 AM EDT - 2 years ago

Tango Therapeutics Announces Presentation of Preclinical Data on TNG260 and Discovery Platform Advances at SITC 37th Annual Meeting

Sep 6, 2022, 7:00 AM EDT - 2 years ago

Tango Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Aug 10, 2022, 7:00 AM EDT - 2 years ago

Tango Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights

Jun 27, 2022, 7:00 AM EDT - 2 years ago

Tango Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes

May 11, 2022, 7:00 AM EDT - 2 years ago

Tango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights

Mar 28, 2022, 7:00 AM EDT - 3 years ago

Tango Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

Mar 8, 2022, 4:57 PM EST - 3 years ago

Tango Therapeutics Announces Presentation of Preclinical Data on TNG908, USP1 Inhibitor Program and Discovery Platform in Three Abstracts Accepted at AACR 2022 Annual Meeting

Market Cap	335.14M
Revenue (ttm)	36.53M
Net Income (ttm)	-101.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-278.51%
Debt to Equity Ratio	0.00

Volume	453,200
Avg Vol	1,355,114
Day's Range	N/A - N/A
Shares Out	107.42M
Stochastic %K	85%
Beta	0.81
Analysts	Strong Sell
Price Target	$11.50